24–25 Nov 2026
IARC
Europe/Paris timezone

Chemotherapy initiation among patients with cancer during the COVID-19 pandemic in Brazil: an interrupted time series analysis

T3-6
25 Nov 2026, 14:45
10m
RC 150 - Auditorium (IARC)

RC 150 - Auditorium

IARC

25 avenue Tony Garnier, Lyon, France
Short oral Prevention Interventions, Policy & Public Health Impact Prevention Interventions, Policy & Public Health Impact

Speaker

Lays Silva de Azevedo (IARC)

Description

Background: the COVID-19 pandemic disrupted cancer care worldwide, but evidence on its impact on treatment initiation is limited. Understanding how the pandemic affected cancer care is essential to strengthen the national health system during or outside of crises. Objective: to estimate the pandemic’s impact on outpatient chemotherapy initiation in Brazil for all cancers combined and for breast, colorectal and lung cancers. Methods: we assessed outpatient chemotherapy authorizations (APAC; 2015-2024), with initiation defined as the first month with chemotherapy after ≥12 months without it. Monthly initiation rates per 100,000 inhabitants were analyzed by interrupted time series with negative binomial regression, seasonal terms, and Newey-West standard errors. Results: we analyzed 35,158,278 APACs from 2.0 million patients (2015-2024) and identified 1.73 million initiations (2016-2024). Patients on chemotherapy remained stable in March 2020 (pandemic onset), and decreased 2.9% in April, still 3.4% above April 2019. In contrast, initiation dropped in March 2020: -10.2% for all cancers (rate ratio [RR] 0.90;95%CI 0.88-0.92), -14.6% for breast (RR 0.85; 95%CI 0.82-0.89), -5.4% for lung (RR 0.95; 95%CI 0.92-0.97) and -4.7% for colorectal cancer (RR 0.95; 95%CI 0.93-0.97; all p<0.001). After the pandemic onset, initiation grew faster than before the pandemic. Fitted rates returned to expected levels by mid-2022 for lung and colorectal and only by late 2024 for breast cancer. Conclusion: during the pandemic, fewer patients started chemotherapy. This may reflect disrupted screening and diagnosis, postponement of treatment by services due to lockdown or by patients fearing infection, or changes in patients' characteristics due to delayed diagnosis.

Author

Co-authors

Presentation materials

There are no materials yet.